Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 3/20 | 0.50 |
| ▸ | ALB | P02768 | 2/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 2/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.40 |
| ▸ | OXTR | P30559 | 2/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.40 |
| ▸ | HTRA2 | O43464 | 3/20 | 0.40 |
| ▸ | HTRA1 | Q92743 | 3/20 | 0.40 |
| ▸ | HTR3A | P46098 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16250025 | 0.98 | SLC5A2 (0.50) | SLC5A2ALBFOLH1ESR1BTK | |
| SCHEMBL19669062 | 0.98 | SLC5A2 (0.50) | SLC5A2ALBFOLH1ESR1BTK | |
| SCHEMBL19365740 | 0.91 | SLC5A2 (0.50) | SLC5A2ALBFOLH1ESR1BTK | |
| SCHEMBL19669056 | 0.88 | CA1 (0.52) | HTR3A | |
| SCHEMBL19365546 | 0.87 | SLC5A2 (0.47) | SLC5A2ALBFOLH1ESR1BTK | |
| SCHEMBL21841338 | 0.86 | SLC5A2 (0.47) | SLC5A2ALBFOLH1ESR1BTK | |
| SCHEMBL19669980 | 0.85 | CA1 (0.51) | HTR3A | |
| SCHEMBL19365748 | 0.85 | CA1 (0.51) | HTR3A | |
| SCHEMBL19365598 | 0.78 | TSHR (0.36) | — | |
| SCHEMBL19670419 | 0.76 | KMT2A (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20180044338-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2018-02-15 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044338-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | SLC5A2 1825/4885ALB 3065/4885FOLH1 3930/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | SLC5A2 1592/4885ALB 3770/4885FOLH1 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.